

Ahmad Y Abuhelwa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4398048/publications.pdf>

Version: 2024-02-01

34
papers

761
citations

686830

13
h-index

525886

27
g-index

35
all docs

35
docs citations

35
times ranked

989
citing authors

#	ARTICLE	IF	CITATIONS
1	Food, gastrointestinal pH, and models of oral drug absorption. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 112, 234-248.	2.0	197
2	A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorptionâ€”Part I: Gastrointestinal pH. <i>AAPS Journal</i> , 2016, 18, 1309-1321.	2.2	90
3	Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5681-5696.	1.4	80
4	A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorptionâ€”Part II: Gastrointestinal Transit Time. <i>AAPS Journal</i> , 2016, 18, 1322-1333.	2.2	58
5	Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 475-482.	1.9	36
6	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. <i>British Journal of Cancer</i> , 2022, 126, 42-47.	2.9	34
7	An introduction to physiologicallyâ€based pharmacokinetic models. <i>Paediatric Anaesthesia</i> , 2016, 26, 1036-1046.	0.6	29
8	Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. <i>Pharmaceutical Research</i> , 2016, 33, 1782-1794.	1.7	27
9	The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. <i>Npj Breast Cancer</i> , 2021, 7, 30.	2.3	22
10	Three-dimensional printed 5-fluorouracil eluting polyurethane stents for the treatment of oesophageal cancers. <i>Biomaterials Science</i> , 2020, 8, 6625-6636.	2.6	21
11	A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1261-1272.	3.0	20
12	Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> , 2021, 13, 1176.	1.7	16
13	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>Scientific Reports</i> , 2020, 10, 18634.	1.6	15
14	Population pharmacokineticâ€pharmacodynamic modelling of liquid and controlledâ€release formulations of oxycodone in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 263-276.	1.2	13
15	Floating and Sustained-Release Characteristics of Effervescent Tablets Prepared with a Mixed Matrix of Eudragit L-100-55 and Eudragit E PO. <i>Chemical and Pharmaceutical Bulletin</i> , 2011, 59, 155-160.	0.6	12
16	Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer. <i>Cancers</i> , 2021, 13, 2001.	1.7	12
17	The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy. <i>Translational Lung Cancer Research</i> , 2022, 11, 432-439.	1.3	12
18	Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 201-215.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. <i>AAPS Journal</i> , 2021, 23, 104.	2.2	8
20	Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 132-138.	0.9	8
21	Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	7
22	Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. <i>Breast</i> , 2021, 58, 57-62.	0.9	6
23	ADVAN-style analytical solutions for common pharmacokinetic models. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 73, 42-48.	0.3	5
24	Population in vitro/in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 181-197.	0.8	5
25	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Resistant Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 720-729.	2.3	5
26	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110090.	1.2	3
27	Effect of Roux-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 232-245.	1.2	3
28	Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials. <i>European Journal of Cancer</i> , 2022, 160, 279-281.	1.3	3
29	A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 479-485.	1.1	2
30	Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. <i>Bladder Cancer</i> , 2022, 8, 81-88.	0.2	2
31	Reply to Auclin et al. Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, 13, 1176; <i>Cancers</i> , 2021, 13, 3763.	1.7	1
32	Novel oral formulations of metformin in semi-solid matrices: Design, characterization and in vitro dissolution testing. <i>Qatar Foundation Annual Research Forum Proceedings</i> , 2012, , BMP47.	0.0	0
33	Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 732622.	1.6	0
34	Photo-cross-linked poly(alkylene-co-tartrate) biodegradable matrices for implantable controlled drug delivery and other biomedical applications. , 2012, , .		0